SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.…
SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma (NASDAQ: SGP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 88 employees.
The shares were at 30.43 USD on 20 November 2026. Its 52-week range is 17.06 USD to 39.92 USD: the price is 23.8% below the high and 78.4% above the low.
Its market capitalisation is 1.02B USD.
SpyGlass Pharma reports return on equity of 40.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 214.15M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 46.67 USD is 53.4% above the current price. The next earnings report is expected on 25 March 2027.